intoDNA Expands Leadership Team with Appointment of Maggie Rougier-Chapman as Chief Business Officer
– Appointment initiates U.S. expansion as STRIDE® scales biopharma services and progresses toward diagnostic readiness –
KRAKÓW, POLAND, January 12, 2025 – intoDNA, a company pioneering functional biomarkers for precision medicine, today announced the appointment of Maggie Rougier-Chapman as Chief Business Officer. In this role, Ms. Rougier-Chapman will lead global business development, strategic partnerships and commercial strategy for STRIDE®, the company’s proprietary platform for functional measurement of DNA damage and DNA repair biomarkers.
The appointment comes at a pivotal stage for intoDNA as the company scales its revenue-generating preclinical drug development services and expands its laboratory footprint to meet growing biopharma demand.
As interest increases in functional biomarkers that directly measure DNA damage and response biology, intoDNA is advancing U.S.-based translational programs and clinical utility studies designed to inform prospective clinical trials required for future diagnostic adoption.
“Ms. Rougier-Chapman has a proven track record of translating differentiated science into scalable precision medicine solutions,” said Magda Kordon-Kiszala, PhD, Founder and CEO of intoDNA. “Her leadership will be instrumental as we expand our U.S. presence, build strategic biopharma partnerships, and prepare STRIDE for clinical adoption.”
“Despite decades of genomic innovation, DNA damage and repair have largely been inferred rather than directly measured,” said Ms. Rougier-Chapman. “STRIDE changes that paradigm by enabling direct functional measurement of DNA damage and DNA repair pathway activity in cells and tissues – delivering clear, decision-grade insight into DNA repair biology that is actionable for drug developers and clinicians. Expanding in the U.S. allows intoDNA to deepen biopharma collaborations while advancing the clinical studies required to support future diagnostic applications.”
Ms. Rougier-Chapman brings more than 20 years of leadership experience across precision oncology, genomics and specialty diagnostics, with deep expertise spanning research use technologies, laboratory developed tests, in vitro diagnostics and companion diagnostic development. She has held commercial leadership roles at Labcorp, PGDx, ArcherDx, and Agilent Technologies, and is the founder of Footprint Bioadvisors, a strategic consultancy advising life sciences and precision medicine companies on commercialization and growth. Ms. Rougier-Chapman holds an MS in Molecular Cancer Biology and a BS in Biology from Duke University.
About intoDNA
intoDNA is a precision medicine company pioneering functional biomarkers that enable direct measurement of DNA damage and DNA repair pathway activity. Through its proprietary STRIDE® platform, the company provides ultra-sensitive, in situ detection and quantification of DNA damage response biology, delivering functional insight that cannot be inferred from genomic sequencing alone.
The STRIDE platform supports biopharma research and translational development today, while the platform advances toward future diagnostic and companion diagnostic applications. As part of its platform, intoDNA is developing dSTRIDE™-HR, a functional homologous recombination deficiency (HRD) assay designed to directly measure DNA repair pathway activity within tumor tissue. By delivering decision-grade functional biomarkers that improve patient stratification, reduce development risk, and accelerate timelines, intoDNA enables more efficient drug development and more precise clinical care. For more information about intoDNA, please visit intoDNA.com, and follow us on LinkedIn.
Media Contact
Megan Prock McGrath
CTD Comms, LLC
[email protected]